XML 58 R46.htm IDEA: XBRL DOCUMENT
v3.23.1

Identifiable Intangible Assets - Additional Information (Detail) $ in Millions | 3 Months Ended
--- | ---
Mar. 31, 2023 USD ($) | Mar. 31, 2022 USD ($)
Finite-Lived Intangible Assets [Line Items] |  |
Amortization of intangible assets useful life |  | 9 years
Amortization of intangible assets | $ 165 | $ 200
Impairment of intangible assets excluding goodwill | $ 178 | $ 149
Minimum [Member] | Measurement input, discount rate [Member] |  |
Finite-Lived Intangible Assets [Line Items] |  |
Business combination, contingent consideration, liability, measurement input | 8.5 |
Maximum [Member] | Measurement input, discount rate [Member] |  |
Finite-Lived Intangible Assets [Line Items] |  |
Business combination, contingent consideration, liability, measurement input | 11 |
In process research and development [Member] | Minimum [Member] |  |
Finite-Lived Intangible Assets [Line Items] |  |
Business combination, contingent consideration, liability, measurement input | 8.5 |
In process research and development [Member] | Minimum [Member] | Measurement input, discount rate [Member] |  |
Finite-Lived Intangible Assets [Line Items] |  |
Business combination, contingent consideration, liability, measurement input | 20 |
In process research and development [Member] | Maximum [Member] |  |
Finite-Lived Intangible Assets [Line Items] |  |
Business combination, contingent consideration, liability, measurement input | 10 |
In process research and development [Member] | Maximum [Member] | Measurement input, discount rate [Member] |  |
Finite-Lived Intangible Assets [Line Items] |  |
Business combination, contingent consideration, liability, measurement input | 90 |
In process research and development [Member] | Generic Pipeline Products [Member] | Development Progress And Changes In Other Key Valuation Assumptions [Member] |  |
Finite-Lived Intangible Assets [Line Items] |  |
Impairment of intangible assets excluding goodwill | $ 19 |
Identifiable product rights [Member] |  |
Finite-Lived Intangible Assets [Line Items] |  |
Impairment of intangible assets excluding goodwill | 159 |
Identifiable product rights [Member] | Regulatory Price And Volume Of Products [Member] |  |
Finite-Lived Intangible Assets [Line Items] |  |
Impairment of intangible assets excluding goodwill | 47 |
Identifiable product rights [Member] | Lenalidomide Product [Member] | Price And Volume Of Products [Member] |  |
Finite-Lived Intangible Assets [Line Items] |  |
Impairment of intangible assets excluding goodwill | 129 |
Japan [Member] | Identifiable product rights [Member] | Updated Market Assumptions [Member] |  |
Finite-Lived Intangible Assets [Line Items] |  |
Impairment of intangible assets excluding goodwill | $ 112 |

X
- Definition The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(2) -URI https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 45 -Paragraph 2 -URI https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274 + Details
Name: | us-gaap_AmortizationOfIntangibleAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Value of input used to measure contingent consideration liability from business combination. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -URI https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput
Namespace Prefix: | us-gaap_
Data Type: | xbrli:decimalItemType
Balance Type: | na
Period Type: | instant

X
- Definition Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References No definition available. + Details
Name: | us-gaap_FiniteLivedIntangibleAssetUsefulLife
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_FiniteLivedIntangibleAssetsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 3 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275 + Details
Name: | us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=teva_GenericPipelineProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | teva_EventBasisAxis=teva_DevelopmentProgressAndChangesInOtherKeyValuationAssumptionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=teva_ProductRightsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | teva_EventBasisAxis=teva_RegulatoryPriceAndVolumeOfProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=teva_LenalidomideProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | teva_EventBasisAxis=teva_PriceAndVolumeOfProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_JP
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | teva_EventBasisAxis=teva_UpdatedMarketAssumptionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |